Last reviewed · How we verify
Cleocin T (CLINDAMYCIN PHOSPHATE)
Cleocin T works by inhibiting protein synthesis in bacteria, preventing them from producing essential proteins and ultimately leading to cell death.
Cleocin T, a marketed clindamycin phosphate topical solution by Pfizer, is positioned in the acne vulgaris treatment market. Its key strength lies in its mechanism of action, which effectively inhibits bacterial protein synthesis, leading to cell death. The primary risk is the key composition patent expiry in 2028, which could open the market to generic competition.
At a glance
| Generic name | CLINDAMYCIN PHOSPHATE |
|---|---|
| Sponsor | Pfizer |
| Drug class | Lincosamide Antibacterial |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
| First approval | 1972 |
Mechanism of action
Mechanism of Action. The mechanism of action of clindamycin in treating acne vulgaris is unknown.
Approved indications
- Acne vulgaris
Common side effects
- Burning
- Itching
- Burning/Itching
- Dryness
- Erythema
- Oiliness/Oily Skin
- Peeling
Drug interactions
- neuromuscular blocking agents
Key clinical trials
- Immediate Restoration of a New Implant With High Primary Stability (NA)
- Utility of Single-dose Oral Antibiotic Prophylaxis in Prevention of Surgical Site Infection in Dermatologic Surgery (PHASE4)
- Preoperative Clindamycin Vaginal Cream Versus Vaginal Cleansing With Povidone-iodine on Postoperative Infections After Cesarean Section (PHASE4)
- Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus Lazertinib (PHASE2)
- Dual vs. Single-Antibiotic Impregnated Cement in Hemiarthroplasty for Femoral Neck Fracture (PHASE3)
- Short Versus Standard of Care Antibiotic Duration for Children Hospitalized for CAP (PHASE4)
- Oral Antimicrobial Treatment vs. Outpatient Parenteral for Infective Endocarditis (PHASE4)
- Evaluation of Topical Dutasteride as a Potential New Therapy for Facial Acne Vulgaris Versus the Triple Combination Therapy (Clindamycin Phosphate 1.2%, Benzoyl Peroxide 3.1%, and Adapalene 0.15% Gel) (NA)
Patents
| Patent | Expiry | Type |
|---|---|---|
| 9789057 | 2026-12-02 | Formulation |
| 11129896 | 2036-09-22 | Method of Use |
| 12303563 | 2036-09-22 | Formulation |
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
| FDA Orange Book | Patents + exclusivity |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Cleocin T CI brief — competitive landscape report
- Cleocin T updates RSS · CI watch RSS
- Pfizer portfolio CI